Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GH55 in MAPK-mutant Advanced Solid Tumors
NCT06310382Phase 2Recruiting
- Sponsor
- Genhouse Bio
- Start
- Dec 2022
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of GH55 in solid tumor (advanced stage), sponsored by Genhouse Bio. Primary endpoints: Dose-limiting Toxicities at 2 years and Adverse Events at 2 years. Started Dec 2022; status: recruiting.
02
Drugs
GH55
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06310382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06310382.